Alzheimer's drugs improve perception

05/2013

Most of the (few) approved Alzheimer’s drugs are cholinesterase inhibitors — that is, they stop the breakdown of the neurotransmitter acetylcholine. A new study explains why they help. It appears they allow signals to enter the brain with more precision and less background noise.

The study involved 13 healthy young adults, some of whom were given the cholinesterase inhibitor galantamine, before listening to a series of modulating tones while focusing on a simple concentration task. The patterns of neural activity demonstrated by those on the drug most closely fit a model in which the signals coming into the brain were sharpened. This was something of a surprise, since it has been generally assumed that the effects would be most pronounced in the ‘higher-order’ processing regions.

The findings are an interesting reminder of the importance of sensory perception for optimal cognition. It should be noted, though, that this sharpening of the signal did occur in an environment in which the stimuli were predictable.

http://www.eurekalert.org/pub_releases/2013-05/vt-taf050713.php

[3407] Moran, R. J., Campo P., Symmonds M., Stephan K. E., Dolan R. J., & Friston K. J.
(2013).  Free Energy, Precision and Learning: The Role of Cholinergic Neuromodulation.
The Journal of Neuroscience. 33(19), 8227 - 8236.

Related News

While everyone agrees that amyloid-beta protein is part of the problem, not everyone agrees that amyloid plaques are the cause (or one of them) of Alzheimer’s. Other forms of amyloid-beta have been pointed to, including floating clumps called oligomers or ADDLs.

A few months ago, I reported on an exciting finding that

The American Academy of Neurology has updated its guidelines on when people with dementia should stop driving.

Another gene has been identified that appears to increase risk of Alzheimer’s. The gene, MTHFD1L, is located on chromosome six.

Previous research has found that unexplained weight loss is an early sign of Alzheimer's.

Amnestic mild cognitive impairment often leads to Alzheimer's disease, but what predicts aMCI?

A pilot study involving 21 institutionalized individuals with moderate-to-severe Alzheimer’s found that, although drinking two 4-oz glasses of apple juice daily for a month produced no change in the Dementia Rating Scale or in the Activities of Daily Living measure, there was a significant (27%)

A pilot study involving 10 patients with moderate Alzheimer's disease, of whom half were randomly assigned to the treatment, has found that two weeks of receiving daily (25 minute) periods of repetitive transcranial magnetic stimulation to the prefrontal

A study involving outpatients with early stage Alzheimer’s found that their performance on some computerized tests of executive function and visual attention, including a simulated driving task, improved significantly after three months of taking

A study involving 54 older adults (66-76) and 58 younger adults (18-35) challenges the idea that age itself causes people to become more risk-averse and to make poorer decisions.

Pages

Subscribe to Latest newsSubscribe to Latest newsSubscribe to Latest health newsSubscribe to Latest news